Allergy Therapeutics (AGY) has reported full-year results to end-June 2025, in line with the July 2025 trading update. Revenues of £55.0m were broadly flat YoY (FY24: £55.2m) on a reported basis, up c2% YoY at CER. The FY25 revenue figure reflects an observed shift in the group’s product mix, driven by German regulators accelerating the transition from non-registered to registered allergen immunotherapy products more quickly than previously anticipated. Post-period, the balance sheet was delever ....
